About Us
An enterprise providing integrated precision microbiota transplantation solutions

Founded in 2016, TreatGut Pharmaceutical Group is a national high-tech enterprise providing integrated precision microbiota transplantation solutions. The Group integrates R&D, intelligent manufacturing, sales, and services, with a focus on human microbiota transplantation. Its business spans microecological health, testing, intervention, therapeutics, and medical big-data mining. After years of development, TreatGut has become an industry leader. Headquartered in Shanghai, the Group adopted group-based management in 2022. It has R&D bases in Shanghai and Xiamen, and subsidiaries in Beijing, Guangzhou, Shenzhen, Chengdu, Xi'an, Xiamen, Shenyang, Ningde, and Yichun. TreatGut Pharmaceutical Group is the only enterprise in China's microbiota transplantation sector to have obtained a Ministry of Science and Technology filing permit for human genetic resources, and the only enterprise in the sector with CNAS accreditation and a complete seven-certificate system. It has established six world-leading core technology platforms, provides five major solutions built on precision microbiota transplantation, and operates a microbiota-bank-centered business system. The Group has developed seven microecology sectors—TreatGut Biology, TreatGut Intelligent Pharmaceuticals, TreatGut Digital Intelligence, TreatGut Medical, TreatGut Health, TreatGut Consumption, and TreatGut Future Microecology Hospital—forming a complete closed-loop microecological healthcare system and an integrated full-industry-chain solutions enterprise. It currently provides professional services to more than 300 medical institutions and has completed over 330,000 microbiota transplantations and gut microbiota tests.